Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 3/20 | 0.76 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.76 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.76 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.76 |
| ▸ | TSHR | P16473 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9272854 | 0.94 | CACNA1F (0.69) | CACNA1FCACNA1DCACNA1SCACNA1CTSHR | |
| SCHEMBL7436006 | 0.87 | TSHR (0.72) | CACNA1FCACNA1DCACNA1SCACNA1CTSHR | |
| SCHEMBL28735860 | 0.86 | CACNA1F (0.63) | CACNA1FCACNA1DCACNA1SCACNA1CTSHR | |
| SCHEMBL16137718 | 0.85 | TSHR (0.70) | CACNA1FCACNA1DCACNA1SCACNA1CTSHR | |
| SCHEMBL7881093 | 0.85 | ALDH1A1 (0.72) | CACNA1FCACNA1DCACNA1SCACNA1CTSHR | |
| SCHEMBL9261647 | 0.85 | CACNA1F (0.59) | CACNA1FCACNA1DCACNA1SCACNA1CTSHR | |
| SCHEMBL3029762 | 0.84 | KDM4E (0.76) | CACNA1FCACNA1DCACNA1SCACNA1CTSHR | |
| SCHEMBL8949694 | 0.84 | CACNA1F (0.64) | CACNA1FCACNA1DCACNA1SCACNA1CTSHR | |
| SCHEMBL9269230 | 0.84 | CACNA1F (0.67) | CACNA1FCACNA1DCACNA1SCACNA1CTSHR | |
| SCHEMBL11817128 | 0.84 | KDM4E (0.76) | CACNA1FCACNA1DCACNA1SCACNA1CTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114516774-A | Preparation method of chiral bromo-1, 4-dihydropyridine compound | 中国科学院成都生物研究所 | 2022-05-20 | — | — | CN | disclosed |
| US-9968574-B2 | Treatment of MCI and Alzheimer's disease | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2018-05-15 | — | — | US | disclosed |
| WO-2011142778-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110118299-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2010132671-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292281-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292281-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-5401746-A | FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND HMG-COA REDUCTASE | BAYER AKTIENGESELLSCHAFT (DE) | 1995-03-28 | — | — | US | disclosed |
| US-5169857-A | Anticholesterol agents | BAYER AKTIENGESELLSCHAFT (DE) | 1992-12-08 | — | — | US | disclosed |
| US-5006530-A | Certain 7-[2,6-diisopropyl-4-phenyl-5-lower alkoxymethyl-pyrid-3-yl]-3,5-dihydroxy-6-enoates and derivatives useful for treating circulatory diseases | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292281-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | CHAT, CHRM2, TPO | CACNA1F 335/4885CACNA1D 330/4885CACNA1S 175/4885 |
| US-20110118299-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | PSEN1, CHAT, CHRM1 | CACNA1F 399/4885CACNA1D 165/4885CACNA1S 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.